AAD 2024 to Feature Topics Including JAK Inhibitors, Biologics
March 6th 2024The American Academy of Dermatology (AAD) will host its annual conference in San Diego from March 8 to March 11, 2024, which will include sessions about Janus kinase (JAK) inhibitors, biologics, and other treatments for skin disorders.
Read More
Stable Treatment Remained in Early Breast Cancer Diagnosis During Pandemic
March 6th 2024A study of patients diagnosed with early breast cancer during the COVID-19 pandemic found that the public health crisis did not produce significant changes in or delays treatment, despite many women presenting with palpable tumors.
Read More
Promise of AI in MS Research and Treatment Showcased at ACTRIMS 2024
March 3rd 2024The poster session at the Americas Committee for Research and Treatment in Multiple Sclerosis (ACTRIMS) Forum 2024 dedicated a section to emerging developments in the use of artificial intelligence (AI) in research and treatment approaches in multiple sclerosis (MS).
Read More
Highlighting Progress, Addressing Unmet Needs in MS Rehabilitation Trials
March 3rd 2024Speakers on the final day of the Americas Committee for Research and Treatment in Multiple Sclerosis (ACTRIMS) Forum 2024 discussed advancements in rehabilitation trials in multiple sclerosis (MS) and unmet research needs.
Read More
Imaging and 3D Modeling a Key Focus at ACTRIMS 2024
March 2nd 2024On day 2 of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024, speakers gave great attention to novel developments in the field of imaging and 3D modeling in multiple sclerosis (MS).
Read More
Spotlighting Efforts to Improve Care Equity, Research Access in MS
March 1st 2024Speakers at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024 focused their attention on avenues to improve research accessibility for investigators and care access for patients with multiple sclerosis (MS).
Read More
PROs May Successfully Risk Stratify Patients With Cutaneous Chronic GVHD
March 1st 2024Two existing, well-validated patient-reported outcome (PRO) measures may be useful as a prognostic marker for mortality and assist with treatment selection for patients with cutaneous chronic graft-vs-host disease (GVHD).
Read More
Advancing the Clinical Understanding of MS: Emerging Concepts Presented at ACTRIMS 2024
March 1st 2024The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 opened with discussions on the novel concepts emerging in multiple sclerosis (MS) research, such as the associations between synaptic loss and hypoxia with disease progression.
Read More
CA-125 Shows Poor Concordance With Radiologic Progression in Ovarian Cancer
March 1st 2024Current treatment guidelines recommend using cancer antigen-125 (CA-125) as a diagnostic marker for ovarian cancer recurrence, but a recent study suggests CA-125 has poor concordance with progressive disease based on RECIST criteria.
Read More
Experts Measure AA Severity With Key Factors, Reach Consensus on Treatment Decisions
February 29th 2024An expert survey using the eDelphi method pinpointed disease duration, treatment response, and mental health as crucial factors in a new multidimensional tool known as Alopecia Areata Severity and Morbidity Index (ASAMI), underlining the importance of personalized treatments for future research incorporating patient perspectives.
Read More